Q-omics provides the consensus-scored ELP3 profile across patient tissues and cancer cell-line models. ELP3 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ELP3 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, ELP3 protein abundance shows 24,579 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight ACC, THCA, and BRCA as cancer lineages where ELP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ELP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ELP3 survival associations across molecular data types. ELP3 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3) and mass-spec protein abundance (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ELP3 RNA expression–survival associations across cancer types. High ELP3 expression shows unfavorable associations in ACC, STAD and BLCA, but favorable associations in KIRC, BRCA and COAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for ELP3 RNA expression.
This table summarizes ELP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 12. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ELP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ELP3 shows lower tumor expression in THCA and BRCA and higher tumor expression in HNSC, UCEC, CHOL and STAD. The THCA box plot shows higher ELP3 RNA expression in normal versus tumor tissue (log2 FC = −0.645, t-test p < 0.001).
This table shows molecular features associated with ELP3 in patient tissues and cancer cell lines. In patient samples, ELP3 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, ELP3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and PANCREAS.
